1426532-71-9

Upstream product

• 20151-40-0 2,4-dibromoquinoline 
• 628292-12-6 (2S)-1-triphenylmethyl-2-pyrrolidinemethanal 
• 179918-60-6 (2S)-1-triphenylmethyl-2-pyrrolidinemethanol 

Downstream Products

• 1426532-77-5 (R)-(2-(4-(trifluoromethyl)phenyl)quinolin-4-yl)((S)-1-tritylpyrrolidin-2-yl)methanol 
• 1426532-78-6 (R)-(2-(pyridin-4-yl)quinolin-4-yl)((S)-1-tritylpyrrolidin-2-yl)methanol 
• 1426532-79-7 (R)-(2-phenylquinolin-4-yl)((S)-1-tritylpyrrolidin-2-yl)methanol 
• 1426532-80-0 (R)-(2-(4-methoxyphenyl)quinolin-4-yl)((S)-1-tritylpyrrolidin-2-yl)methanol 
• 1426532-85-5 (R)-((S)-pyrrolidin-2-yl)(2-(4-(trifluoromethyl)phenyl)quinolin-4-yl)methanol 
• 1426532-87-7 (R)-(2-phenylquinolin-4-yl)((S)-pyrrolidin-2-yl)methanol 
• 1426532-88-8 (R)-(2-(4-methoxyphenyl)quinolin-4-yl)((S)-pyrrolidin-2-yl)methanol 

Relevant academic research and scientific papers

Optimized quinoline amino alcohols as disruptors and dispersal agents of Vibrio cholerae biofilms

The biofilm state is an integral part of the lifecycle of many bacterial pathogens. Identifying inhibitors as molecular probes against bacterial biofilms has numerous potential biomedical applications. Here we report quinoline amino alcohol 20 as a highly potent disruptor of V. cholerae biofilms. Additionally, 20 was able to disperse preformed biofilms, an activity exhibited by few compounds with biofilm inhibiting activity.

Development of quinoline-based disruptors of biofilm formation against Vibrio cholerae

Biofilm formation is a major cause of bacterial persistence in nosocomial infections, leading to extended treatment times and increased rates of morbidity and mortality. Despite this, there are currently no biofilm inhibitors approved for clinical use. Th